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August 3, 2010:525–30atients who progress to symptomatic Chagas’ disease, we sug-
ested AAB measurement in asymptomatic Chagas’ patients for
ardiomyopathy and megacolon risk assessment.
We now present first indications supporting our concept. At a
edian 31 months (range 27 to 47 months) after the primary
atient classification, we were able to contact 36 of our primarily
symptomatic patients, of whom 15 were AAB-negative and 21
AB-positive. In the second investigation, none of the AAB-
egative patients reported clinical symptoms and had electrocar-
iographic characteristics indicative of progression to symptomatic
hagas’ disease. Among the AAB-positive patients of the primary
nvestigation, a 40-year-old woman presented with cardiomyopa-
hy diagnosed by electrocardiogram, demonstrating the progres-
ion to symptomatic chronic Chagas’ disease. In the primary study,
his woman had had the typical cardiomyopathy AAB composition
f beta1-AAB combined with M2-AAB. A second patient, a
1-year-old woman, presented with clinically diagnosed megaco-
on. This woman was burdened in the primary investigation with
2-AAB positivity and borderline positivity for beta2-AAB,
hich suggest megacolon risk.
Despite the tentative nature of the information presented here,
e hope that this first successful step in the evaluation of AAB
easurement in asymptomatic Chagas’ patients for cardiomyopa-
hy and megacolon risk assessment will further our concept and
ncourage other scientists to take part in its evaluation. However,
onsidering the time- and cost-intensive bioassay used for the
AB measurement (1), the development of cost-limited but
tandardized and more universally available enzyme-linked immu-
osorbent assays seems to be an essential prerequisite. Initiatives in
he enzyme-linked immunosorbent assay development should, in
ur view, first focus on M2-AAB. Both patients who progressed to
ymptomatic Chagas’ disease presented with M2-AAB in the
symptomatic stage. Therefore, we would like to suggest M2-AAB
s the preferential tool in the risk assessment of asymptomatic
hagas’ patients. The use of M2-AAB for risk assessment was also
een as a promising strategy by others (2). Using M2-AAB as a risk
arker would also account for the function of M2-AAB in driving
he alterations in the autonomic nerve system (3,4) that have
requently been discussed in the pathogenesis of Chagas’ heart and
astrointestinal disease.
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uantity and Quality
n Medical Research
e read with interest the papers by Kaul et al. (1) and Stone et al.
2), published in a recent issue of the Journal. Both highlight
ividly the all too commonly found errors and limitations in
urrent medical literature. While the causes of such a state of affairs
re multiple, we believe the sheer volume of scientific papers
ublished nowadays is a major contributor.
To illustrate this point, a PubMed listings search using the
riteria “human, randomized controlled trial” reveals an astounding
rowth in the number of studies published in each 10-year strata,
tarting February 4, 1950: 1950 to 1960, no items found; 1960 to
970, 1,076 studies found; 1970 to 1980, 9,622 studies; 1980
o 1990, 36,066 studies; 1990 to 2000, 91,194 studies; and 2000 to
010, 136,109 studies found. In the past year alone, 11,276 such
apers were found using PubMed.
While such a rate of growth may be partly due to widespread use
f standardized methodology and the establishment of a worldwide
cientific community, less exalted factors such as industry pressures
3) and the “publish or perish” drive (4) may also be at play. It is,
herefore, difficult to argue that each or even most of these studies
ill be sound in their conceptual development, performance,
nalysis, and interpretation.
In truth, the scientific enterprise has in many ways become the
cientific industry, and the challenges we now face transcend
echnical or methodological limitations. Rather than quantity, we
ust now focus on quality and its indispensable antecedents,
ompetence and integrity.
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UPITER “Moderate CKD”
ubgroup Is Not Truly “Moderate”
hronic Kidney Disease
iven that trials of lipid lowering in patients with chronic kidney
isease (CKD) requiring dialysis have been neutral (1), and the
nly evidence for lipid-lowering therapy in patients with CKD not
equiring dialysis is based on secondary analyses, such as the
ravastatin Pooling Project (2), it is commendable that a subgroup
efined by kidney function was examined in JUPITER (Justifica-
ion for the Use of Statins in Prevention–an Intervention Trial
valuating Rosuvastatin), as reported recently in this journal (3).
owever, we do not believe that it is appropriate to call this a
ubgroup with “moderate CKD.”
The JUPITER CKD subgroup is influenced by the limitations
f the Modified Diet in Renal Disease (MDRD) equation for
stimating glomerular filtration rate (GFR) and the study inclusion
riteria. Moderate CKD is defined by a GFR of 30 to 59 ml/min,
ith or without other evidence of kidney damage, but should be
resent for 3 months to be truly “chronic” kidney disease (4). The
DRD GFR equation uses the serum creatinine, age, sex, and
frican American ethnicity to estimate GFR but underestimates
FR at higher levels (5). The characteristics of this JUPITER
ubgroup that suggest the term “moderate CKD” is inappropriate
re as follows:
. In the CKD subgroup, 50% of participants had a GFR between
51 and 58 ml/min, and 25% had a GFR between 58 and 60
ml/min (Table 1 [3]). At least one-fourth of patients could have
been misclassified simply due to variability in the creatinine
assay (6). The authors do not report whether creatinine was
measured centrally or what calibration procedures were used.
. Female participants were substantially over-represented in the
CKD subgroup, whereas African-American participants were
substantially under-represented (Table 1 [3]). The multipliers
in the MDRD equation result in lower GFRs for women and
higher GFRs for African Americans with the same serum
creatinine, and the problem of a universal cutoff of 60 ml/min
causing 50% more women than men to be classified as having
CKD has been described (7).
. The 10-year age difference between women and men in the
inclusion criteria may result in more females having a GFR60 ml/min. In an age-specific MDRDGFR “reference range”
in a population free of vascular disease, hypertension, diabetes,
or kidney disease, the median GFR in women age 60 to 64
years was 10 ml/min lower compared with men age 50 to 54
years (7).
The results were described as similar with the Cockroft-Gault
quation, but it would be interesting to see how the characteristics,
r indeed the classification, of the patients was altered.
We do not question the effect of the intervention in the patients
escribed or the use of the MDRD equation for this purpose.
owever, patients seen by nephrologists and cardiologists with a
FR between 30 and 59 ml/min (“moderate” CKD by the
/DOQI [Kidney Disease Outcomes Quality Initiative] classifi-
ation) have a high prevalence of diabetes and cardiovascular
isease (excluded by design in the JUPITER trial) and higher,
ather than lower, systolic blood pressure than people with normal
idney function. We suggest that this JUPITER subgroup is better
escribed as “patients with an MDRD GFR 60 ml/min on
occasion” to avoid inappropriate extrapolation of these results.
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